Apolipoprotein E genotypes predict attendance rates at lipid clinic
R Frikke-Schmidt1, H H Wittrup, A Tybjaerg-Hansen
1Department of Clinical Biochemistry, Herlev University Hospital, Denmark.
Atherosclerosis
|February 13, 2001
Summary
Apolipoprotein E (APOE) genotype influences lipid clinic referrals. Specific APOE variants like epsilon44 increase hypercholesterolemia referrals, while epsilon22, epsilon42, epsilon43, and epsilon44 increase hypertriglyceridemia referrals.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Biochemistry
Background:
- Apolipoprotein E (APOE) genotype's role in lipid clinic referral is not well-established.
- APOE influences lipid metabolism and cardiovascular risk.
Purpose of the Study:
- To investigate the association between APOE genotype and referral rates to lipid clinics.
- To compare APOE genotype frequencies in patients with hypercholesterolemia and hypertriglyceridemia against the general population.
Main Methods:
- Genotype distributions were compared between lipid clinic patients (156 hypercholesterolemic, 83 hypertriglyceridemic) and a general population sample (9241 individuals).
- Statistical analysis (chi-squared test) was used to determine significant differences in genotype frequencies.
Main Results:
- APOE genotype frequencies differed significantly between the general population and both patient groups.
- For hypercholesterolemia, APOE epsilon44 was associated with a 2-fold increased referral rate, while epsilon32 showed a 2-fold decrease compared to epsilon33.
- For hypertriglyceridemia, APOE epsilon22, epsilon42, epsilon43, and epsilon44 showed significantly increased referral rates (13-, 3-, 1.5-, and 3-fold, respectively) compared to epsilon33.
Conclusions:
- APOE genotype is associated with lipid clinic referral rates.
- Hypercholesterolemic individuals with APOE epsilon44 and hypertriglyceridemic individuals with APOE epsilon22, epsilon42, epsilon43, or epsilon44 are more frequently referred to lipid clinics.
More Related Videos
Related Concept Videos
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...